ADAMTS19

Across TCGA pan-cancer cohorts, ADAMTS19 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAMTS19 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ADAMTS19 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADAMTS19 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, UCEC, and ACC are the cancer types where ADAMTS19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.241	0.549	<.001	24	view →
UCEC	DFS	Median	All	0.983	0.823	.002	22	view →
ACC	DFS	Median	III,IV	0.010	0.458	<.001	21	view →
LIHC	OS	Median	All	0.224	0.679	.003	11	view →
LGG	OS	Median	All	0.294	0.799	.005	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADAMTS19–ESCA (DFS)

Open the ESCA breakdown →